Search results

Cactus, Inc.WHD is entering the second half of 2026 with faster earnings growth, expanding international exposure and substantial liquidity. Second-quarter results showed that the Cactus

Prothena Corporation PRTA reported second-quarter 2026 adjusted loss per share (excluding restructuring costs) of 32 cents, narrower than the Zacks Consensus Estimate of a loss of 39 cents per

Ocugen OCGN reported a second-quarter 2026 loss of 7 cents per share, which was wider than the Zacks Consensus Estimate as well as the year-ago loss of 5 cents. Higher research and development

Joby Aviation, Inc. JOBY reported a second-quarter 2026 loss of 25 cents per share, wider than the Zacks Consensus Estimate of a loss of 23 cents. In the year-ago quarter, JOBY reported a loss of 41

Westlake Corporation WLK logged adjusted earnings of $2.01 per share for the second quarter of 2026, topping the Zacks Consensus Estimate of $1.93. Adjusted earnings improved sharply from an

Adient plc ADNT reported adjusted earnings of 48 cents per share in the third quarter of fiscal 2026, which increased 6.7% year over year but missed the Zacks Consensus Estimate of 53 cents by 9.4%

Dave Inc. DAVE recently delivered another solid quarter in second-quarter 2026, with revenues rising 30% year over year to $170.8 million. According to the results released last week, adjusted

Array Digital Infrastructure, Inc. AD delivered second-quarter 2026 results above the Zacks Consensus Estimate, with earnings of 64 cents per share topping the 62-cent estimate by 3.2%. Revenues of

Sunoco LP SUN is strengthening its fuel distribution platform with the planned acquisition of Offen Petroleum (Offen) for approximately $600 million in an all-cash transaction. The deal is expected

Wynn Resorts, Limited WYNN reported second-quarter 2026 adjusted earnings of $1.24 per share, topping the Zacks Consensus Estimate of $1.01. Operating revenues of $1.86 billion beat the $1.84

Kodiak Sciences KOD announced that it initiated a global late-stage ALTO study evaluating KSI-501 in patients with diabetic macular edema (DME). KSI-501 is an investigational bispecific therapy that

Universal Display Corporation OLED delivered second-quarter earnings above the Zacks Consensus Estimate, but revenues fell short as material sales weakened. Earnings of $1.06 per share topped the

Ambiq Micro, Inc. AMBQ reported second-quarter 2026 non-GAAP loss of 7 cents per share, narrower than the Zacks Consensus Estimate of a loss of 26 cents. The company had incurred a loss of 43 cents